 |
|
Obesity found to be a risk factor for multiple myeloma
July 20, 2007PHILADELPHIA -- An obese person is more likely than a lean person to develop multiple myeloma, according to researchers from Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health. Their findings indicate that Body Mass Index (BMI) - a statistical measure that scales weight to height - provides an indicator for one's risk of developing multiple myeloma, a cancer of the blood cells that produce antibodies. Multiple myeloma currently affects more than 50,000 people in the U.S., and the five-year survival rates of the cancer are below 40 percent.
The study, published in the July issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, takes its data from over 100,000 participants in the on-going Nurses' Health Study and Health Professionals Follow-up Study, two similar large-scale studies. The study findings were similar to those from previously published studies that included smaller numbers of multiple myeloma patients, and/or were based on a one-time recording of height and weight.
"I find the results of these studies encouraging, since they show consistent results about the first risk factor for multiple myeloma that people can actually modify," said the study's lead author Brenda M. Birmann, Sc.D., a researcher in the Department of Medicine at Brigham and Women's Hospital and Harvard Medical School. "Treatment options for this disease are improving, but it is also important to identify risk factors that could be modified. We would like to learn how to prevent its occurrence."
The Brigham and Women's Hospital-based Nurses' Health Study has followed the health of female registered nurses since 1976, and the Health Professionals Follow-up Study, based at Harvard School of Public Health, has followed males from several health professions since 1986. These studies recorded height, weight and physical activity for each person enrolled, as well as diet, medications, smoking habits and other health behaviors, and has updated that information every two to four years. Of the 136,623 participants who qualified for their study protocol, Birmann and her colleagues confirmed 215 cases of multiple myeloma.
Body Mass Index (BMI) is computed by dividing a person's weight by the square of their height. A BMI between 18.5 and 25 is considered optimal, a BMI of 25-29 is considered overweight, and a BMI of 30 or higher is considered obese.
The association between BMI and multiple myeloma was strongest among men with a BMI of 30 or more. When compared with leaner men (those with a BMI below 22), obese men, the researchers said, were over twice as likely to develop multiple myeloma. The effect was less pronounced among overweight or obese women, yet those women also had an increased risk.
The study also looked at whether regular exercise is related to risk of multiple myeloma. There was not a clear effect of exercise on risk, although the results among women suggested that those who exercise more might have a lower risk. "We cannot say with certainty that exercise reduces the risk of multiple myeloma, but there is ample evidence that regular exercise offers many other health benefits," Birmann said.
The study findings do show, however, that the effect of BMI on risk of multiple myeloma is separate from any possible effect of physical activity.
According to Birmann, previous research has identified possible biological links between obesity and multiple myeloma. For example, adipocytes, cells found in fat tissue, produce a cell signal, called interleukin-6 (IL-6), which promotes the immune system's inflammation response. In obese people, this can cause an overproduction of IL-6, which in turn creates a cellular environment that sustains multiple myeloma. "The IL-6 chemical pathway is one possible way obesity could influence the risk of developing diseases like cancer or cardiovascular disease, but the answer might also lie in other relationships between obesity and cancer," Birmann said.
Further research, she said, will uncover more about the relationships between obesity and cancers such as multiple myeloma. The researchers believe their findings may lead to examination in greater detail of the BMI/multiple myeloma link, including the role of IL-6 and other chemical signals, energy metabolism, and other risk factors such as weight change or weight cycling.
American Association for Cancer Research
The Brigham and Women's Hospital-based Nurses' Health Study has followed the health of female registered nurses since 1976, and the Health Professionals Follow-up Study, based at Harvard School of Public Health, has followed males from several health professions since 1986. These studies recorded height, weight and physical activity for each person enrolled, as well as diet, medications, smoking habits and other health behaviors, and has updated that information every two to four years. Of the 136,623 participants who qualified for their study protocol, Birmann and her colleagues confirmed 215 cases of multiple myeloma.
Body Mass Index (BMI) is computed by dividing a person's weight by the square of their height. A BMI between 18.5 and 25 is considered optimal, a BMI of 25-29 is considered overweight, and a BMI of 30 or higher is considered obese.
The association between BMI and multiple myeloma was strongest among men with a BMI of 30 or more. When compared with leaner men (those with a BMI below 22), obese men, the researchers said, were over twice as likely to develop multiple myeloma. The effect was less pronounced among overweight or obese women, yet those women also had an increased risk.
The study also looked at whether regular exercise is related to risk of multiple myeloma. There was not a clear effect of exercise on risk, although the results among women suggested that those who exercise more might have a lower risk. "We cannot say with certainty that exercise reduces the risk of multiple myeloma, but there is ample evidence that regular exercise offers many other health benefits," Birmann said.
The study findings do show, however, that the effect of BMI on risk of multiple myeloma is separate from any possible effect of physical activity.
According to Birmann, previous research has identified possible biological links between obesity and multiple myeloma. For example, adipocytes, cells found in fat tissue, produce a cell signal, called interleukin-6 (IL-6), which promotes the immune system's inflammation response. In obese people, this can cause an overproduction of IL-6, which in turn creates a cellular environment that sustains multiple myeloma. "The IL-6 chemical pathway is one possible way obesity could influence the risk of developing diseases like cancer or cardiovascular disease, but the answer might also lie in other relationships between obesity and cancer," Birmann said.
Further research, she said, will uncover more about the relationships between obesity and cancers such as multiple myeloma. The researchers believe their findings may lead to examination in greater detail of the BMI/multiple myeloma link, including the role of IL-6 and other chemical signals, energy metabolism, and other risk factors such as weight change or weight cycling.
American Association for Cancer Research
Myeloma Current Events and Myeloma News RSSThe miseries of allergies just may help prevent some cancers, study finds
There may be a silver -- and healthy -- lining to the miserable cloud of allergy symptoms: Sneezing, coughing, tearing and itching just may help prevent cancer -- particularly colon, skin, bladder, mouth, throat, uterus and cervix, lung and gastrointestinal tract cancer, according to a new Cornell study.
Supercomputer provides massive computational boost to biomedical research at TGen
In less time than the blink of an eye, the Translational Genomics Research Institute's new supercomputer at Arizona State University can do operations equal to every dollar in the recent Wall Street bailout.
On the trail of a targeted therapy for blood cancers
nvestigators from the Herman B Wells Center for Pediatric Research at the Indiana University School of Medicine are focusing on a family of blood proteins that they hope holds a key to decreasing the toxic effects of chemotherapy in children and adults.
Mayo researchers explore issues related to multiple myeloma treatment
Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients.
VCU Massey Cancer Center Spearheads Novel Clinical Study for Lymphoma Patients
The Virginia Commonwealth University Massey Cancer Center recently opened a National Cancer Institute (NCI)-sponsored, phase II clinical study for certain sub-types of non-Hodgkin's lymphoma.
Researchers discover how rheumatoid arthritis causes bone loss
Researchers have discovered key details of how rheumatoid arthritis (RA) destroys bone, according to a study published in the Aug. 22 edition of the Journal of Biological Chemistry.
Clinical study shows biological and clinical activity in relapsed leukemia patients
Finbarr Cotter, M.D., Ph.D., Professor of the Institute of Cell and Molecular Science at Barts and The London School of Medicine, today presented in an oral session "Clinical Caspase Activation in CLL by GCS-100: a Phase 2 Study" at the 10th International Conference on Malignant Lymphoma (10-ICML).
OHSU Discovery May Lead to Early Cancer Detection
OHSU pancreatic cancer expert Brett Sheppard, M.D., and colleagues in the OHSU Oregon Stem Cell Center, have developed antibodies that recognize pancreatic cancer; Sheppard is presenting these findings this week during Digestive Disease Week in San Diego.
Immune system pathway identified to fight allergens, asthma
For the first time, researchers from the University of Pittsburgh School of Medicine have identified genetic components of dendritic cells that are key to asthma and allergy-related immune response malfunction.
U of Minnesota study finds thalidomide shows promise for treatment of recurrent ovarian cancer
Thalidomide, a drug blamed in the 1950s for causing birth defects, is now showing promise as a safe and effective treatment for women with recurrent ovarian cancer, according to a study led by a University of Minnesota Cancer Center researcher.
More Myeloma Current Events and Myeloma News Articles
 | 100 Questions and Answers About Myeloma (100 Questions & Answers about . . .) (100 Questions & Answers about . . .) by Asad Bashey, Rafat Abonour Whether you are a newly diagnosed myeloma patient, a survivor, or a friend or relative of either, this book offers help. The only text to provide the doctor s and patient s views, 100 Questions & Answers About Myeloma gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. Written by a... |
 | Multiple Myeloma: The Plain English Handbook for Patients and Care Givers by Robert J. Heller A concise and helpful overview of the disease, including therapies, medications, problems, and lifestyle changes. Many helpful hints in an easy to understand format which avoids a lot of hard to understand terminology in favor of a more light-hearted approach. Includes reproducible forms and many references to other... |
 | Myeloma (The Biology of Cancer) by Jerome E., Ph.d. Tanner Myeloma is a form of cancer that rises from white blood cells called B lymphocytes. The disease usually causes malignant cells to grow within bone marrow. These cells interfere with marrow function as well as the immune system. Risk for myeloma has been linked to old age, being overweight, and environmental factors such as radiation exposure. Myeloma draws upon the most current medical research... |
 | Multiple Myeloma: Translational and Emerging Therapies (Translational Medicine) by Kenneth C. Anderson Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting new text, edited by lauded authorities on the topic, stands as the only available reference to assemble, review, and synthesize the latest studies on translational therapies, and clearly explains the impact of molecular pathogenesis, biology, and prognostic... |
 | Multiple Myeloma Medical Guide by Qontro Medical Guides The Multiple Myeloma Medical Guide is a publication which has been designed to better help readers understand Multiple Myeloma. This Qontro Medical Guide has been designed with the reader in mind, and is a useful information source for readers at all levels looking to learn more about Multiple Myeloma. The Multiple Myeloma Medical Guide is highly recommended for those interested in understanding... |
 | Myeloma: Biology and Management by James S. Malpas, Daniel E. Bergsagel, Robert A. Kyle, Kenneth C. Anderson Completely revised and updated, the 3rd Edition of this premier resource provides cutting-edge coverage of the epidemiology, immunology, and hematology of myelomaall in one convenient reference. A team of leading international authorities in myeloma research presents a worldwide perspective on the most recent developments in management and therapeutic options, as well as the latest clinical... |
 | Multiple Myeloma and Related Plasma Cell Disorders (Hematologic Malignancies) Building on the considerable expertise of the dysproteinemia unit at Mayo Clinic, this book spans the gamut from multiple myeloma, the most frequent and most serious of the monoclonal gammopathies, to the rarest related disorders. Laboratory evaluation, associations with nonhematologic disorders, monoclonal gammopathies of undetermined significance, the more obscure plasma cell dyscrasias,... |
 | Treatment of Multiple Myeloma and Related Disorders Due to major advances in understanding the biology and pathogenesis of the disease, the management of multiple myeloma is changing rapidly. New diagnostic and prognostic criteria have been introduced, and treatment options are multiplying with high-dose chemotherapy regimens, stem cell transplants, and the development of novel agents and immune-based strategies that target tumor cells directly. ... |
 | Multiple Myelomas, An Issue of Hematology / Oncology Clinics (The Clinics: Internal Medicine) by Kenneth C. Anderson Although treatable with conventional and high dose therapies, multiple myeloma (MM) remains incurable. However, recent advances in oncogenomics, coupled with increased understanding of the role of the bone marrow (BM) microenvironment in MM pathogenesis, has provided the basis for a new treatment paradigm targeting the tumor cell in the BM milieu to overcome conventional drug resistance and... |
| Myeloma Therapy:: Pursuing the Plasma Cell (Contemporary Hematology) Therapeutic options for patients with myeloma have radically changed over the past ten years. Beginning with the advances in therapy resulting from the use of high dose therapy and autologous bone marrow or stem cell transplant, we have more than doubled the median survival for patients as a whole, and have now a wealth of different biology based treatment approaches for our patients in all... |
| © 2008 BrightSurf.com |